Cite

    Ellingson, B. et al. (2017). Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro-oncology. 19 (1), pp. 89-98. [Online].